On April 18th, Dr. Leping Li, Senior Vice President of Haihe Pharmaceuticals, along with Dr. Xuming Liu, Vice President of CMC, and Feng Zhou, Senior Director of CMC, and other team members visited Jiuzhou Pharmaceuticals to carry out investigation activities. Wang Bin, Co-President of Jiuzhou Pharmaceutical and other company leaders attended the reception.

At the meeting, Dr. Li Leping expressed his deep gratitude to Jiuzhou Pharmaceuticals for providing high quality new drug development services for Haihe Drugs, helping to stabilize the commercial supply of new drug Gumetinib API and guaranteeing the smooth delivery of the project. Dr. Li also awarded Jiuzhou Pharmaceutical with “Excellent Strategic Partner Award”.

Based on the good cooperation in the previous period, in 2018, Jiuzhou Pharmaceuticals entered into a strategic alliance with Haihe Pharmaceuticals. Since the cooperation, the one-stop API service capability of Jiuzhou Pharmaceutical's CDMO team has been highly recognized by Haihe Pharmaceuticals. over the past 5 years, Jiuzhou Pharmaceuticals has provided Haihe Pharmaceuticals with services such as API (including intermediates) development and production at different stages of new drug R&D, which further expands Haihe Pharmaceuticals' ability in innovative drug discovery, R&D and production.

In 2023, the cooperation between the two sides will reap the fruits of win-win. in March, Haihe Drugs' Class 1 new drug, Gumetinib tablets, was approved for marketing. As a core strategic partner, Jiuzhou Pharmaceuticals provides one-stop solutions and comprehensive services for Haihe Drugs in terms of API IND China-US dual reporting for innovative drugs, supply of APIs for clinical use, NDA filing (New Drug Application), and long-term supply of APIs for commercialization.

Creating value and upgrading trust. The in-depth strategic cooperation between Jiuzhou Pharmaceuticals and Haihe Pharmaceuticals has produced significant results, and the strategic partnership between the two sides has stepped up to a new level, further demonstrating Jiuzhou Pharmaceuticals' strength and level in the field of one-stop service for API customization, and the effectiveness of the CDMO brand has been demonstrated once again.

On April 18th, Dr. Leping Li, Senior Vice President of Haihe Pharmaceuticals, along with Dr. Xuming Liu, Vice President of CMC, and Feng Zhou, Senior Director of CMC, and other team members visited Jiuzhou Pharmaceuticals to carry out investigation activities. Wang Bin, Co-President of Jiuzhou Pharmaceutical and other company leaders attended the reception.

At the meeting, Dr. Li Leping expressed his deep gratitude to Jiuzhou Pharmaceuticals for providing high quality new drug development services for Haihe Drugs, helping to stabilize the commercial supply of new drug Gumetinib API and guaranteeing the smooth delivery of the project. Dr. Li also awarded Jiuzhou Pharmaceutical with “Excellent Strategic Partner Award”.

Based on the good cooperation in the previous period, in 2018, Jiuzhou Pharmaceuticals entered into a strategic alliance with Haihe Pharmaceuticals. Since the cooperation, the one-stop API service capability of Jiuzhou Pharmaceutical's CDMO team has been highly recognized by Haihe Pharmaceuticals. over the past 5 years, Jiuzhou Pharmaceuticals has provided Haihe Pharmaceuticals with services such as API (including intermediates) development and production at different stages of new drug R&D, which further expands Haihe Pharmaceuticals' ability in innovative drug discovery, R&D and production.

In 2023, the cooperation between the two sides will reap the fruits of win-win. in March, Haihe Drugs' Class 1 new drug, Gumetinib tablets, was approved for marketing. As a core strategic partner, Jiuzhou Pharmaceuticals provides one-stop solutions and comprehensive services for Haihe Drugs in terms of API IND China-US dual reporting for innovative drugs, supply of APIs for clinical use, NDA filing (New Drug Application), and long-term supply of APIs for commercialization.

Creating value and upgrading trust. The in-depth strategic cooperation between Jiuzhou Pharmaceuticals and Haihe Pharmaceuticals has produced significant results, and the strategic partnership between the two sides has stepped up to a new level, further demonstrating Jiuzhou Pharmaceuticals' strength and level in the field of one-stop service for API customization, and the effectiveness of the CDMO brand has been demonstrated once again.

On April 18th, Dr. Leping Li, Senior Vice President of Haihe Pharmaceuticals, along with Dr. Xuming Liu, Vice President of CMC, and Feng Zhou, Senior Director of CMC, and other team members visited Jiuzhou Pharmaceuticals to carry out investigation activities. Wang Bin, Co-President of Jiuzhou Pharmaceutical and other company leaders attended the reception.

At the meeting, Dr. Li Leping expressed his deep gratitude to Jiuzhou Pharmaceuticals for providing high quality new drug development services for Haihe Drugs, helping to stabilize the commercial supply of new drug Gumetinib API and guaranteeing the smooth delivery of the project. Dr. Li also awarded Jiuzhou Pharmaceutical with “Excellent Strategic Partner Award”.

Based on the good cooperation in the previous period, in 2018, Jiuzhou Pharmaceuticals entered into a strategic alliance with Haihe Pharmaceuticals. Since the cooperation, the one-stop API service capability of Jiuzhou Pharmaceutical's CDMO team has been highly recognized by Haihe Pharmaceuticals. over the past 5 years, Jiuzhou Pharmaceuticals has provided Haihe Pharmaceuticals with services such as API (including intermediates) development and production at different stages of new drug R&D, which further expands Haihe Pharmaceuticals' ability in innovative drug discovery, R&D and production.

In 2023, the cooperation between the two sides will reap the fruits of win-win. in March, Haihe Drugs' Class 1 new drug, Gumetinib tablets, was approved for marketing. As a core strategic partner, Jiuzhou Pharmaceuticals provides one-stop solutions and comprehensive services for Haihe Drugs in terms of API IND China-US dual reporting for innovative drugs, supply of APIs for clinical use, NDA filing (New Drug Application), and long-term supply of APIs for commercialization.

Creating value and upgrading trust. The in-depth strategic cooperation between Jiuzhou Pharmaceuticals and Haihe Pharmaceuticals has produced significant results, and the strategic partnership between the two sides has stepped up to a new level, further demonstrating Jiuzhou Pharmaceuticals' strength and level in the field of one-stop service for API customization, and the effectiveness of the CDMO brand has been demonstrated once again.